GLIS3, a susceptibility gene for T1D and T2D and monogenic forms of the disease (Taha et al, 2003; Senée et al, 2006; Dimitri et al, 2011), decreases the expression of the splicing regulator SRSF6, and we have previously shown that SRSF6 inhibition hampers human β-cell function and viability (Juan-Mateu et al, 2018). The gene discussed is SRSF6; the disease is type 2 diabetes mellitus.